Results 231 to 240 of about 1,995 (245)

Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine

Vaccine
The tetravalent dengue vaccine TAK-003 and the 9-valent human papillomavirus (9vHPV) vaccine regimens are potentially compatible, with overlapping target age groups, facilitating inclusion of TAK-003 into established immunization programs.This phase 3, open-label, randomized, multicenter trial was conducted in Thailand to investigate the immunogenicity
Shibadas Biswal, Nicolas Folschweiller
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

EE562 Cost-Effectiveness of the Dengue Vaccine TAK-003 in Thailand

Value in Health, 2023
J. Shen, E. Kharitonova, S. Biswal, M. Sharma, S. Aballea, A. Tytuła, J. Zawieja, P. Towle, R. Hanley, S. Rungmaitree   +9 more
openaire   +1 more source

Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study

Lancet Infectious Diseases, The
Dengue is a substantial public health challenge in tropical regions, and is considered a global health threat owing to its expanding geographical range and increasing incidence as a result of climate change. Despite the availability of tetravalent dengue vaccines, real-world evidence on their effectiveness is scarce.
Roberto Oliveira, Julio Croda, Natalie E Dean   +2 more
exaly   +3 more sources

Safety signal detected: Anaphylaxis after attenuated dengue vaccine (TAK-003) – Brazil, march 1, 2023-march 11, 2024

Vaccine
The aim was to describe cases of anaphylaxis following the Attenuated Dengue Vaccine (TAK-003) in Brazil, from March 1, 2023, to March 11, 2024. A descriptive study of anaphylaxis cases following TAK-003 was conducted, as reported in the National System of Surveillance of Adverse Events Following Immunization (AEFI).
Jadher, Percio, Carla Dinamerica, Kobayashi, Roberta Mendes Abreu, Silva, Ana Karolina Barreto Berselli, Marinho, Leon, Capovilla, Paulo Henrique Santos, Andrade, Martha Elizabeth Brasil, da Nóbrega, Cibelle Mendes, Cabral, Monica Brauner, de Moraes, Guilherme Loureiro, Werneck, Eder Gatti, Fernandes   +10 more
openaire   +2 more sources

Protocol Systematic review of health economic evaluation studies of TAK-003 and CYD-TDV

Title: Economic Evaluation of Dengue Vaccines Approved in Brazil: A Systematic Review Background: The application of Health Technology Assessment (HTA) in healthcare is essential as technological advancements and demands on health systems continue to grow (Nemzoff et al., 2023). Dengue, a major infectious disease in Brazil, significantly contributes to
openaire   +1 more source

EPH47 Modeling the Impact of the Vaccine Candidate TAK-003 on the Incidence of Dengue in French Overseas Territories

Value in Health, 2023
A. Nucit, R. Moreau, M. Massetti, C. Strub, E. Kharitonova, A. Tytula, J. Zawieja, H. Leleu, J. Shen   +8 more
openaire   +1 more source

TAK-003 Dengue Vaccine Clinical Experience: An Integrated Safety Analysis by Baseline Dengue Serostatus

2023
Patel, Sanjay S, Rauscher, Martina, Mandaric, Sanja, Pang, Hang   +3 more
openaire   +1 more source

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country

Vaccine, 2023
Vianney Tricou, Paul Collini, ZENAIDA MOJARES   +2 more
exaly  

EE528 Cost-Effectiveness Analysis of the TAK-003 Dengue Vaccine Introduction in Argentina

Value in Health
A Uruena, N Giglio, PV Micone, S Rapaport, P Towle, D Shih, J Langer, A Carbone   +7 more
openaire   +1 more source

Clinical Safety of Tetravalent Dengue Vaccine, TAK-003, Among Participants With and Without Prior Flavivirus Vaccine Exposure

2023
Escudero, Ian, Shibadas Biswal, Rauscher, Martina, Pang, Hang, Suely Tuboi, Lloyd, Eric, Tricou, Vianney, Folschweiller, Nicolas, Patel, Sanjay S   +8 more
openaire   +1 more source